Introduction and Objective: It is unclear whether DKD incidence varies by world region of birth. We examined whether the incidence of DKD (defined as the Kidney Disease Improving Global Outcomes (KDIGO) categories 2-4) differs between immigrants and long-term residents (LTRs) with T2D in Ontario, Canada.
Methods: This retrospective cohort study used population-based linked databases to examine age-sex standardized incidence rates of DKD based on the most recent creatinine and urinary albumin-creatinine ratio (ACR) during the baseline (2012-16) and observation (2017-21) periods among adults aged 20-80 years with pre-existing T2D. We used the gamma distribution method to test for significant differences between immigrants and LTRs.
Results: We included 647,210 individuals (mean age 61.6 years, 44.9% female, 152,778 immigrants). Overall standardized incidence varied (category 2: 76.4; 3: 31.0; 4: 15.9 per 1000 person-years). Immigrants from Southeast Asia had significantly higher incidence of categories 2 and 3 (91.1, 36.4 respectively; p<0.05) and a similar incidence of category 4 (16.6) versus LTRs. Incidence of categories 2-4 was lower among immigrants from East Asia (62.2, 18.5, 7.2 respectively) and several other regions versus LTRs (p<0.05). Disparities in incidence narrowed as KDIGO category increased.
Conclusion: DKD incidence varies substantially by world region of birth.
S. Mohamed: None. J. Lipscombe: None. L. Lipscombe: Other Relationship; Novo Nordisk Canada Inc. C. Kenaszchuk: None. D. Thiruchelvam: None. G.S. Fazli: None. B.R. Shah: None. L. Rosella: None. C. Ke: Advisory Panel; Sanofi. Speaker's Bureau; AstraZeneca.
Novo Nordisk Network for Healthy Populations
